Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 132 of 153 entries
Sorted by: Best Match Show Resources per page
Type 2 diabetes market.

Nature reviews. Drug discovery

Gershell L.
PMID: 15902771
Nat Rev Drug Discov. 2005 May;4(5):367-8. doi: 10.1038/nrd1723.

No abstract available.

Cite
Gershell L. Type 2 diabetes market. Nat Rev Drug Discov. 2005;4(5):367-8doi: 10.1038/nrd1723.
Gershell, L. (2005). Type 2 diabetes market. Nature reviews. Drug discovery, 4(5), 367-8. https://doi.org/10.1038/nrd1723
Gershell, Leland. "Type 2 diabetes market." Nature reviews. Drug discovery vol. 4,5 (2005): 367-8. doi: https://doi.org/10.1038/nrd1723
Gershell L. Type 2 diabetes market. Nat Rev Drug Discov. 2005 May;4(5):367-8. doi: 10.1038/nrd1723. PMID: 15902771.
Copy Download .nbib Format: NLM
[Nihilism or polyteism in diabetic care?].

Lakartidningen

Linnersten L.
PMID: 18574987
Lakartidningen. 2008 May 7-13;105(19):1415.

No abstract available.

Cite
Linnersten L. Nihilism eller polyteism inom diabetesvården? [Nihilism or polyteism in diabetic care?]. Lakartidningen. 2008;105(19):1415
Linnersten, L. (2008). Nihilism eller polyteism inom diabetesvården? [Nihilism or polyteism in diabetic care?]. Lakartidningen, 105(19), 1415.
Linnersten, Lars. "Nihilism eller polyteism inom diabetesvården?" [Nihilism or polyteism in diabetic care?]. Lakartidningen vol. 105,19 (2008): 1415.
Linnersten L. Nihilism eller polyteism inom diabetesvården? [Nihilism or polyteism in diabetic care?]. Lakartidningen. 2008 May 7-13;105(19):1415. Swedish. PMID: 18574987.
Copy Download .nbib Format: NLM
Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk.

Metabolism: clinical and experimental

La Vecchia C.
PMID: 21550082
Metabolism. 2011 Oct;60(10):1357-8. doi: 10.1016/j.metabol.2011.03.011. Epub 2011 May 06.

No abstract available.

Cite
La Vecchia C. Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism. 2011;60(10):1357-8doi: 10.1016/j.metabol.2011.03.011.
La Vecchia, C. (2011). Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism: clinical and experimental, 60(10), 1357-8. https://doi.org/10.1016/j.metabol.2011.03.011
La Vecchia, Carlo. "Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk." Metabolism: clinical and experimental vol. 60,10 (2011): 1357-8. doi: https://doi.org/10.1016/j.metabol.2011.03.011
La Vecchia C. Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism. 2011 Oct;60(10):1357-8. doi: 10.1016/j.metabol.2011.03.011. Epub 2011 May 06. PMID: 21550082.
Copy Download .nbib Format: NLM
An update on the comparative effectiveness and safety of medications for type 2 diabetes.

Annals of internal medicine

Goldstein MR, Mascitelli L.
PMID: 22007052
Ann Intern Med. 2011 Oct 18;155(8):562-3; author reply 563. doi: 10.7326/0003-4819-155-8-201110180-00020.

No abstract available.

Cite
Goldstein MR, Mascitelli L. An update on the comparative effectiveness and safety of medications for type 2 diabetes. Ann Intern Med. 2011;155(8):562-3; author reply 563doi: 10.7326/0003-4819-155-8-201110180-00020.
Goldstein, M. R., & Mascitelli, L. (2011). An update on the comparative effectiveness and safety of medications for type 2 diabetes. Annals of internal medicine, 155(8), 562-3; author reply 563. https://doi.org/10.7326/0003-4819-155-8-201110180-00020
Goldstein, Mark R, and Mascitelli, Luca. "An update on the comparative effectiveness and safety of medications for type 2 diabetes." Annals of internal medicine vol. 155,8 (2011): 562-3; author reply 563. doi: https://doi.org/10.7326/0003-4819-155-8-201110180-00020
Goldstein MR, Mascitelli L. An update on the comparative effectiveness and safety of medications for type 2 diabetes. Ann Intern Med. 2011 Oct 18;155(8):562-3; author reply 563. doi: 10.7326/0003-4819-155-8-201110180-00020. PMID: 22007052.
Copy Download .nbib Format: NLM
A note on the A1chieve study and the importance of disseminating our results.

The Journal of the Association of Physicians of India

Shah SN.
PMID: 24482978
J Assoc Physicians India. 2013 Jan;61(1):5.

No abstract available.

Cite
Shah SN. A note on the A1chieve study and the importance of disseminating our results. J Assoc Physicians India. 2013;61(1):5
Shah, S. N. (2013). A note on the A1chieve study and the importance of disseminating our results. The Journal of the Association of Physicians of India, 61(1), 5.
Shah, Siddharth N. "A note on the A1chieve study and the importance of disseminating our results." The Journal of the Association of Physicians of India vol. 61,1 (2013): 5.
Shah SN. A note on the A1chieve study and the importance of disseminating our results. J Assoc Physicians India. 2013 Jan;61(1):5. PMID: 24482978.
Copy Download .nbib Format: NLM
Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".

Circulation

Koh KK.
PMID: 30640544
Circulation. 2019 Jan 15;139(3):416-417. doi: 10.1161/CIRCULATIONAHA.118.037209.

No abstract available.

Cite
Koh KK. Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". Circulation. 2019;139(3):416-417doi: 10.1161/CIRCULATIONAHA.118.037209.
Koh, K. K. (2019). Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". Circulation, 139(3), 416-417. https://doi.org/10.1161/CIRCULATIONAHA.118.037209
Koh, Kwang Kon. "Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)"." Circulation vol. 139,3 (2019): 416-417. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.037209
Koh KK. Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". Circulation. 2019 Jan 15;139(3):416-417. doi: 10.1161/CIRCULATIONAHA.118.037209. PMID: 30640544.
Copy Download .nbib Format: NLM
[Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].

Kardiologiia

Kobalava ZD, Yeshniyazov NV, Medovchshikov VV, Khasanova ER.
PMID: 31002044
Kardiologiia. 2019 Apr 17;59(4):76-87. doi: 10.18087/cardio.2019.4.10253.

Type 2 diabetes mellitus (T2DM) has gone beyond the professional interests of one specialty. T2DM, cardiovascular (CV) diseases and chronic kidney disease, considered from the standpoint of a single cardio-reno-metabolic continuum, place a heavy economic burden on society. At...

Cite
Kobalava ZD, Yeshniyazov NV, Medovchshikov VV, et al. [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]. Kardiologiia. 2019;59(4):76-87doi: 10.18087/cardio.2019.4.10253.
Kobalava, Z. D., Yeshniyazov, N. V., Medovchshikov, V. V., & Khasanova, E. R. (2019). [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]. Kardiologiia, 59(4), 76-87. https://doi.org/10.18087/cardio.2019.4.10253
Kobalava, Zh D, et al. "[Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]." Kardiologiia vol. 59,4 (2019): 76-87. doi: https://doi.org/10.18087/cardio.2019.4.10253
Kobalava ZD, Yeshniyazov NV, Medovchshikov VV, Khasanova ER. [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis]. Kardiologiia. 2019 Apr 17;59(4):76-87. doi: 10.18087/cardio.2019.4.10253. Russian. PMID: 31002044.
Copy Download .nbib Format: NLM
[Gliflozines, a new approach to the treatment of type 2 diabetes].

La Revue du praticien

Rigalleau V, Blanco-Baillet L, Hugo M, Pupier É, Gin H.
PMID: 30512322
Rev Prat. 2016 Feb;66(2):127-130.

No abstract available.

Cite
Rigalleau V, Blanco-Baillet L, Hugo M, et al. Les gliflozines, une nouvelle voie dans le traitement du diabète de type 2. [Gliflozines, a new approach to the treatment of type 2 diabetes]. Rev Prat. 2016;66(2):127-130
Rigalleau, V., Blanco-Baillet, L., Hugo, M., Pupier, �. �., & Gin, H. (2016). Les gliflozines, une nouvelle voie dans le traitement du diabète de type 2. [Gliflozines, a new approach to the treatment of type 2 diabetes]. La Revue du praticien, 66(2), 127-130.
Rigalleau, Vincent, et al. "Les gliflozines, une nouvelle voie dans le traitement du diabète de type 2." [Gliflozines, a new approach to the treatment of type 2 diabetes]. La Revue du praticien vol. 66,2 (2016): 127-130.
Rigalleau V, Blanco-Baillet L, Hugo M, Pupier É, Gin H. Les gliflozines, une nouvelle voie dans le traitement du diabète de type 2. [Gliflozines, a new approach to the treatment of type 2 diabetes]. Rev Prat. 2016 Feb;66(2):127-130. French. PMID: 30512322.
Copy Download .nbib Format: NLM
Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure.

Cardiology

Seferovic JP, Seferovic PM.
PMID: 32200379
Cardiology. 2020;145(5):321-323. doi: 10.1159/000506731. Epub 2020 Mar 20.

No abstract available.

Cite
Seferovic JP, Seferovic PM. Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure. Cardiology. 2020;145(5):321-323doi: 10.1159/000506731.
Seferovic, J. P., & Seferovic, P. M. (2020). Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure. Cardiology, 145(5), 321-323. https://doi.org/10.1159/000506731
Seferovic, Jelena P, and Seferovic, Petar M. "Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure." Cardiology vol. 145,5 (2020): 321-323. doi: https://doi.org/10.1159/000506731
Seferovic JP, Seferovic PM. Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure. Cardiology. 2020;145(5):321-323. doi: 10.1159/000506731. Epub 2020 Mar 20. PMID: 32200379.
Copy Download .nbib Format: NLM
Type 2 diabetes care and the law of endocrine parsimony.

JPMA. The Journal of the Pakistan Medical Association

Kalra S, Gupta Y.
PMID: 31431786
J Pak Med Assoc. 2019 Aug;69(8):1222-1223.

Diabetes care has become more and more complex and challenging. For the practicing physician, advances in pathophysiology and diagnostic/ monitoring tools are welcome, as they enhance understanding of the syndrome, its causation, and its natural history. The surfeit of...

Cite
Kalra S, Gupta Y. Type 2 diabetes care and the law of endocrine parsimony. J Pak Med Assoc. 2019;69(8):1222-1223
Kalra, S., & Gupta, Y. (2019). Type 2 diabetes care and the law of endocrine parsimony. JPMA. The Journal of the Pakistan Medical Association, 69(8), 1222-1223.
Kalra, Sanjay, and Gupta, Yashdeep. "Type 2 diabetes care and the law of endocrine parsimony." JPMA. The Journal of the Pakistan Medical Association vol. 69,8 (2019): 1222-1223.
Kalra S, Gupta Y. Type 2 diabetes care and the law of endocrine parsimony. J Pak Med Assoc. 2019 Aug;69(8):1222-1223. PMID: 31431786.
Copy Download .nbib Format: NLM
Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States.

Diabetes, obesity & metabolism

Dawwas GK, Leonard CE, Garg M, Vouri SM, Smith SM, Flory JH, Genuardi MV, Park H.
PMID: 31903713
Diabetes Obes Metab. 2020 Apr;22(4):705-710. doi: 10.1111/dom.13949. Epub 2020 Jan 19.

We conducted a cross-sectional analysis using a database from commercial health plans in the United States to describe trends in the use of antidiabetic medications among patients with type 2 diabetes and heart failure (HF) from 2006 through 2017....

Cite
Dawwas GK, Leonard CE, Garg M, et al. Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes Obes Metab. 2020;22(4):705-710doi: 10.1111/dom.13949.
Dawwas, G. K., Leonard, C. E., Garg, M., Vouri, S. M., Smith, S. M., Flory, J. H., Genuardi, M. V., & Park, H. (2020). Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes, obesity & metabolism, 22(4), 705-710. https://doi.org/10.1111/dom.13949
Dawwas, Ghadeer K, et al. "Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States." Diabetes, obesity & metabolism vol. 22,4 (2020): 705-710. doi: https://doi.org/10.1111/dom.13949
Dawwas GK, Leonard CE, Garg M, Vouri SM, Smith SM, Flory JH, Genuardi MV, Park H. Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes Obes Metab. 2020 Apr;22(4):705-710. doi: 10.1111/dom.13949. Epub 2020 Jan 19. PMID: 31903713.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Nature reviews. Endocrinology

Deacon CF.
PMID: 32929230
Nat Rev Endocrinol. 2020 Nov;16(11):642-653. doi: 10.1038/s41574-020-0399-8. Epub 2020 Sep 14.

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available molecules that interact with the catalytic site of DPP4 without disturbing...

Cite
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642-653doi: 10.1038/s41574-020-0399-8.
Deacon, C. F. (2020). Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature reviews. Endocrinology, 16(11), 642-653. https://doi.org/10.1038/s41574-020-0399-8
Deacon, Carolyn F. "Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus." Nature reviews. Endocrinology vol. 16,11 (2020): 642-653. doi: https://doi.org/10.1038/s41574-020-0399-8
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Nov;16(11):642-653. doi: 10.1038/s41574-020-0399-8. Epub 2020 Sep 14. PMID: 32929230.
Copy Download .nbib Format: NLM
Showing 121 to 132 of 153 entries